Rosenbaum & Rosenbaum, P.C. | March 18, 2016 | Defective Drugs
The defective drug, Xarelto, a blood thinner and anticoagulant drug manufactured to treat and prevent blood clots is now the source of thousands of lawsuits commenced against the drug’s developers, Johnson & Johnson and Bayer.
The US Food and Drug Administration approved Xarelto as a treatment for deep vein thrombosis, atrial fibrillation, and pulmonary embolism as well as for patients who are recovering from a major surgery such as a hip replacement. However, the lawsuit that has now been filed against the drug manufactures, those responsible for creating these defective drugs, claims patients were not adequately warned about the major bleeding events. In addition, the drug studies, medical journals and advertisements proved to be undependable and inadequately monitored.
According to news sources, there may be evidence that the drug’s manufactures left out critical data that would have indicated the problems with Xarelto and given a more accurate account of the test studies done on the blood thinner before coming to market. Some of the problems or side effects patients are experiencing with Xarelto include rapid bleeding occurrences that can result in extended hospitalization or death. However, with the concealment of important data, the drug was approved with these devastating consequences attached.
These drug developers concealed significant, dangers side-effects linked to Xarelto and chose to advertise the drug in an inaccurately positive light. Unfortunately, there isn’t any treatment to stop the bleeding from Xarelto, potentially causing very serious injuries. The negligence of the manufactures of Xarelto as well as the failure from the FDA has led to thousands of contrary events including significant blood lose and death.